Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

p300 modulates nuclear morphology in prostate cancer.

Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, Tindall DJ.

Cancer Res. 2005 Feb 1;65(3):708-12.

2.
3.

Differential expression of nuclear lamins in normal and cancerous prostate tissues.

Coradeghini R, Barboro P, Rubagotti A, Boccardo F, Parodi S, Carmignani G, D'Arrigo C, Patrone E, Balbi C.

Oncol Rep. 2006 Mar;15(3):609-13.

PMID:
16465420
4.

SRC-3 is required for prostate cancer cell proliferation and survival.

Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY, Tsai MJ.

Cancer Res. 2005 Sep 1;65(17):7976-83.

5.

Androgen deprivation increases p300 expression in prostate cancer cells.

Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ.

Cancer Res. 2007 Apr 1;67(7):3422-30.

6.

p300 in prostate cancer proliferation and progression.

Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ.

Cancer Res. 2003 Nov 15;63(22):7638-40.

7.

Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.

Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW.

Clin Cancer Res. 2004 May 15;10(10):3465-73.

8.

p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM.

Cancer Res. 2002 Jan 1;62(1):141-51.

9.

Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.

Gong J, Zhu J, Goodman OB Jr, Pestell RG, Schlegel PN, Nanus DM, Shen R.

Oncogene. 2006 Mar 30;25(14):2011-21.

PMID:
16434977
10.

Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.

Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant'Agnese A, Messing EM, Yeh S.

Cancer Res. 2005 Nov 1;65(21):9807-16.

11.

Nuclear matrix proteins as biomarkers in prostate cancer.

Leman ES, Getzenberg RH.

J Cell Biochem. 2002;86(2):213-23. Review.

PMID:
12111991
12.
13.

Identification of nuclear matrix proteins in the cancer and normal rat prostate.

Getzenberg RH, Pienta KJ, Huang EY, Coffey DS.

Cancer Res. 1991 Dec 15;51(24):6514-20.

15.
16.

Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.

Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F, Walther R.

Cancer Lett. 2008 Aug 8;266(2):171-85. doi: 10.1016/j.canlet.2008.02.047. Epub 2008 Apr 1.

PMID:
18384941
17.

p300 regulates p63 transcriptional activity.

MacPartlin M, Zeng S, Lee H, Stauffer D, Jin Y, Thayer M, Lu H.

J Biol Chem. 2005 Aug 26;280(34):30604-10. Epub 2005 Jun 17.

18.

The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.

Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S.

Mol Cancer Res. 2009 Jan;7(1):142-55. doi: 10.1158/1541-7786.MCR-08-0117.

19.

Com-1/p8 acts as a putative tumour suppressor in prostate cancer.

Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD, Fodstad O.

Int J Mol Med. 2006 Nov;18(5):981-6.

PMID:
17016631
20.

Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.

Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC.

Clin Cancer Res. 2009 Jul 1;15(13):4322-35. doi: 10.1158/1078-0432.CCR-08-3157. Epub 2009 Jun 9.

Supplemental Content

Support Center